Journal for ImmunoTherapy of Cancer (Nov 2020)
194 A multicenter characterization of chronic toxicities following adjuvant anti-PD-1 therapy for high risk resected melanoma
- Andrew Haydon,
- Rebecca Johnson,
- Iman Osman,
- Janice Mehnert,
- Suthee Rapisuwon,
- Douglas Johnson,
- Ryan Sullivan,
- Matteo Carlino,
- Alexander Menzies,
- Prachi Bhave,
- James Patrinely,
- Aleigha Lawless,
- Amelia Sawyers,
- Maya Dimitrova,
- Hui Yeohc,
- Marisa Palmeri,
- Elizabeth Davis,
- Georgina Long
Affiliations
- Andrew Haydon
- 7Alfred Health, Victoria, Australia
- Rebecca Johnson
- 2Melanoma Institute of Australia, Sydney, Australia
- Iman Osman
- 6Perlmutter Cancer Center at NYU Langone, New York, NY, USA
- Janice Mehnert
- 6Perlmutter Cancer Center at NYU Langone, New York, NY, USA
- Suthee Rapisuwon
- 10Lombardi Comprehensive Cancer Center, Washington, DC, USA
- Douglas Johnson
- 9Vanderbilt University Medical Center, Nashville, TN, USA
- Ryan Sullivan
- 3Massachusetts General Hospital, Boston, MA, USA
- Matteo Carlino
- 4Crown Princess Mary Cancer Centre, Sydney, Australia
- Alexander Menzies
- 2Melanoma Institute of Australia, Sydney, Australia
- Prachi Bhave
- 4Crown Princess Mary Cancer Centre, Sydney, Australia
- James Patrinely
- 1Vanderbilt University, Nashville, TN, USA
- Aleigha Lawless
- 3Massachusetts General Hospital, Boston, MA, USA
- Amelia Sawyers
- 5New York University School of Medicine, New York, NY, USA
- Maya Dimitrova
- 6Perlmutter Cancer Center at NYU Langone, New York, NY, USA
- Hui Yeohc
- 7Alfred Health, Victoria, Australia
- Marisa Palmeri
- 8Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
- Elizabeth Davis
- 9Vanderbilt University Medical Center, Nashville, TN, USA
- Georgina Long
- 2Melanoma Institute of Australia, Sydney, Australia
- DOI
- https://doi.org/10.1136/jitc-2020-SITC2020.0194
- Journal volume & issue
-
Vol. 8,
no. Suppl 3
Abstract
No abstracts available.
